Lusutrombopag

Drug Profile

Lusutrombopag

Alternative Names: MULPLETA; S-888711

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Shionogi
  • Class Small molecules; Thiazoles
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Thrombocytopenia
  • Discontinued Immune thrombocytopenic purpura

Most Recent Events

  • 08 Jun 2016 Shionogi initiates a phase I/II trial in Thrombocytopenia in Japan (JapicCTI-163289)
  • 01 Dec 2015 Launched for Thrombocytopenia in Japan (PO) - First global launch
  • 28 Sep 2015 Registered for Thrombocytopenia in Japan (PO) - first global approval
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top